Nephros signs exclusive license & supply deal with Medica; min purchases €4.98M-€6.3M/yr through 2030

NEPHROS INC

Replaces prior Dec 2023 License & Supply Agreement with Medica; that agreement terminated.
Nephros receives exclusive right to market & sell Products using Medica's Medisulfone ultrafiltration tech.
Minimum annual purchases from Medica: €4.976M (2026), €5.349M (2027), €5.750M (2028), €6.000M (2029), €6.300M (2030).
Term through Dec 31, 2030; Nephros may terminate for convenience with 90 days' notice; Medica may terminate for uncured monetary default.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.